Skip to content

Autologous Cord Blood Mononuclear Cells for Bronchopulmonary Dysplasia in Very Preterm Neonates

Autologous Cord Blood Mononuclear Cells for Bronchopulmonary Dysplasia in Very Preterm Neonates

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02999373
Enrollment
62
Registered
2016-12-21
Start date
2018-07-01
Completion date
2020-01-01
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary Dysplasia, Neonatal Death, Premature

Keywords

prevention, Bronchopulmonary Dysplasia, preterm, cord blood mononuclear cells

Brief summary

Rationale: Pre-clinical animal studies provide robust evidence regarding the beneficial effect of cord blood-derived mononuclear cells (MNCs) for experimental bronchopulmonary dysplasia (BPD). This single-center, non-randomized, controlled, blinded trial assessed the effect of a single intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing BPD in very preterm neonates, a high-risk population.

Interventions

Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection

Sponsors

Guangdong Women and Children Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
0 Weeks to 32 Weeks
Healthy volunteers
No

Inclusion criteria

(1) born at the study hospital; (2) singleton birth; (3) GA \<32 weeks; (4) free of severe congenital anomalies or genetic syndromes; (5) without clinical chorioamnionitis; (6) the mother was negative for hepatitis B (HBsAg and/or HBeAg), hepatitis C (anti-HCV), syphilis, HIV (anti-HIV-1 and -2), and IgM against cytomegalovirus, rubella, toxoplasma, and herpes simplex viruses; (7) consent was obtained from the parents or guardians; and (8) after processing, UCB cells were available.

Design outcomes

Primary

MeasureTime frameDescription
bronchopulmonary dysplasia at 36 weeks of postmenstrual age or the discharge home36 weeks of postmenstrual age or the dischargebronchopulmonary dysplasia rate

Secondary

MeasureTime frameDescription
number of patients with severe BPD in survivors36 weeks of postmenstrual age or the dischargesevere BPD in survivors
number of patients died before discharge from hospitalbefore discharge from hospitalmortality before discharge from hospital
the duration of mechanical ventilationbefore discharge from hospitalOther outcomes

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026